-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
Important drug targets yielded by new genetic study of HD
8 min read
A genetic study confirms that minute differences in DNA repair genes can influence the age of HD symptom onset.
-
Thinking clearly about the earliest symptoms of HD and which brain regions control them
8 min read
HD reaches more brain structures than we thought: new research broadens our understanding of the earliest signs of HD
-
How NOT to write a news article about a clinical trial
5 min read
A confusing story about a huntingtin lowering trial is published in the Telegraph, but cool new stuff is happening!
-
Huntington's Disease Therapeutics Conference 2016 – day 3
8 min read
Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
-
Huntington's Disease Therapeutics Conference 2016 – day 2
7 min read
Strategies for getting rid of mutant huntingtin & clinical trial updates: day 2 of the HD therapeutics conference
-
Huntington's Disease Therapeutics Conference 2016 – day 1
12 min read
Proteins and DNA – Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
-
Harnessing the power of viruses to treat Huntington's disease
7 min read
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
-
Through a Broader Lens: Looking at Non-Motor Symptoms in HD
8 min read
Sleep deficits precede motor problems in HD
-
Looking Past the Spin: Results from a Clinical Trial of Cysteamine
6 min read
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.
-
A recycled drug gives us new insight in to HD
7 min read
An existing drug could give a boost to HD brain cells – but it may need more testing before it’s back in the clinic
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
